Glanzmann Thrombasthenia (GT) is an autosomal recessive platelet disorder characterized by impaired fibrinogen binding due to mutations in the integrin receptor GPIIbIIIa. GT has been studied using animal models, heterologous expression systems and patient-derived platelets. Patient-specific human induced pluripotent stem cells (hiPSC) offer new approaches for modeling blood disorders in vitro by differentiating hiPSC-derived haematopoietic stem cells (HSCs) into myeloid and lymphoid lineages. We have generated patient-specific hiPSC of an 18 year old female carrying two novel compound heterozygous GPIIb mutations. HiPSC clones were in vitro differentiated into HSCs, megakaryocytes (MKs) and platelets using a specific protocol. As expected MKs and platelets from both control and GT-hiPSC showed normal morphology in haemacolour stains and similar expression of CD42b (GPIb). No surface or intracellular expression of CD41 protein (GPIIb) was detected in MKs and platelets from GT-hiPSC. Upon activation with Thromboxan A and ADP, peripheral blood-derived and GT-hiPSC-derived platelets showed reduced PAC1 binding, surface spreading and adherence on fibrinogen, resembling the in vitro phenotype of GT. We demonstrate that GThiPSC-derived MKs and platelets recapitulate the disease phenotype in vitro.
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This model offers the ability to study pathophysiology in MKs which are difficult to obtain from patients with bleeding disorders. In the future it can be a useful tool to elucidate the pathomechanism of disease-causing mutations in platelet receptors and thereby facilitating the in vitro evaluation of new therapeutic antiplatelet agents. After gene correction it might even open the road for gene therapy and transplantation of "corrected" hIPSC derived HSCs. Rationale: Acute viral myocarditis (VM) is one of the leading causes of heart failure in young adults, lacking specific therapy. Osteonection (SPARC) is a nonstructural matrix protein modulating cell-matrix interaction in the heart, and has been implicated in cardiac remodeling. Whether SPARC may regulate cardiac inflammation and necrosis in VM through its matri-cellular function is unknown.
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Methods and results:
To address the implication of SPARC in VM, a human coxsackie B3 (CVB3) murine model of VM was performed in SPARC-null and WT animals. SPARC transcript-and protein levels significantly increased by 100% percent 1 week after CVB3 injection compared to control injection. Furthermore, absence of SPARC increased the mortality (4 out of 6 in null vs. 3 out of 7 in WT at 15 days), which was associated with increased cardiac inflammation and necrosis (9% ± 3.03 in KO vs. 1.3% ± 0.24 in WT). Concordantly, Adenoviral SPARC (adSPARC) over-expression, prior to CVB3 injection, improved the survival in both SPARCnull and WT mice, and reduced cardiac inflammation and necrosis by 55 percent in the SPARC null mice. Most importantly, adSPARC over-expression in WT animals resulted in improved cardiac function after viral injury as compared to control vector (fractional shortening was 28,2% ± 0,6 vs. 21,2% ± 0,8 respectively). Intra-vital microscopy of the cremaster muscle allowed us to study leukocyte behavior and permeability in vivo. This demonstrated significantly increased permeability with 450% and decreased leukocyte velocities in SPARC null mice upon TNF-α stimulation, in line with increased leukocyte extravasation. Moreover we performed in vivo measurement of the endothelial glycocalyx, a gel like structure at the luminal side of endothelial cells which is important in endothelial barrier properties. We found glycocalyx quality to be significantly diminished in SPARC null mice. VCAM-1 was further identified as a possible mediator of proper leukocyte recruitment through increased SPARC, since VCAM-1 staining clearly colocalized with SPARC at the endothelial cell level.
Conclusion:
Here, we demonstrated a protective role of SPARC in VM by improving cardiac function and reducing cardiac inflammation, necrosis and overall mortality. This protective role can be attributed to SPARC by improving endothelial barrier properties and thereby prohibiting exaggerated leukocyte recruitment. Clinical Relevance: As therapy for acute myocarditis is lacking and mainly supportive, we believe SPARC may be a novel target for the treatment of VM.
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Study of the role of the new endolysosomal receptors two pore channels (TPCN1 and TPCN2) in human, mouse and rat heart V. Purpose: Mammalian two-pore channel proteins (TPCN1, TPCN2) are recently identified as ion channels in intracellular endosomes and lysosomes whose role at cardiac level is completely unknown. Our aim was to study the cardiac effect of knocking out TPCN1 in mice as well as studying the regulation of expression of cardiac TPCN1 and TPCN2 by cardiovascular diseases and metabolic conditions. Methods: We carried out a differential proteomic analysis of murine cardiac ventricle between controls (n=3) and knockout (n=3) mice for TPCN1 (TPCN1 KO). Two dimensional gel electrophoresis was performed. Detection was made with SYPRO Ruby and identification by MALDI-TOF/TOF. RT-qPCR was used to quantify mRNA expression and inmunoblotting to confirm protein expression of TPCN1 and TPCN2 in left-ventricular myocardium from patients with heart failure (HF, n = 36) without diabetes mellitus of ischaemic (ICM, n = 16) or dilated (DCM, n = 20) cardiomyopathy, and non-diseased donors (CTL, n = 6), as well as in three/four week-old male Sprague-Dawley rats fed with standard or high-fat diet and in male adult Zucker diabetic fatty (ZDF) and lean (ZL) rats. Results: In murine cardiac tissue, we observed 27 differential spots (foldchange>1.8 and p<0.05), all elevated in TPCN1 KO versus wt mice. The most relevant protein change observed was FABP3 (Fatty acid binding protein 3) and it was validated by western blot (p=0.0313). Cardiac transcript expression of TPCN1 (p=0.018) and TPCN2 (p=0.001) increased in heart failure patients relative to controls. Increases remained significant for TPCN2 in all groups (ICM, p=0.008; DCM, p=0.001) but for TPCN1 only in DCM (p=0.015). In male Sprague-Dawley rats, we observed an increase in TPCN1 (p=0.012) and TPCN2 (p=0.0041) cardiac mRNA levels in high fat (n=13) versus control (n=13) rats. On the contrary, in Zucker rats, we observed a decreased of TPCN1 (p=0.0001) and TPCN2 (p=0.0005) mRNA levels in ZL (n=10) versus ZDF (n=10). Conclusion: In TPCN1 KO mice heart, there is an increase in FABP3 which suggest that cardiac fatty acid transport is altered by the lack of TPCN1. Both receptors seem to be key regulators in the rat heart metabolism, since their gene expression levels are regulated by diet and obesity. TPCN1 expression is clearly increased in HF as a whole also tended towards a cardiomyophaty difference. TPCN2 up regulation could also be involved in a general mechanism underlying heart failure, at least with ICM and DCM etiology. The current data provide the first evidence that the endolysosomal system might be involved in the regulation of cardiac metabolism.
Glucose depletion is essential for the calorie-restriction-mediated cardiac angiogenesis via PKA/AMPK-dependent autophagy
